The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis
1Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, Texas. Electronic address: nicole.rich@utsouthwestern.edu.
2Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern, Dallas, Texas.
3Harold C. Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, Texas; Department of Surgery, UT Southwestern, Dallas, Texas.
4Karsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center and Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California.
5Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, Texas.
6Harold C. Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, Texas; Department of Radiation Oncology, UT Southwestern, Dallas, Texas.
7Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, Texas; Center for Human Nutrition, UT Southwestern, Dallas, Texas.
Abstract
Background & aims: Cancer cachexia is a wasting syndrome associated with functional impairment and reduced survival that impacts up to 50% of patients with gastrointestinal cancers. However, data are limited on the prevalence and clinical significance of cachexia in patients with hepatocellular carcinoma (HCC).
Methods: We performed a retrospective cohort study of patients diagnosed with HCC at 2 United States health systems between 2008 and 2018. Patient weights were recorded 6 months prior to and at time of HCC diagnosis. Cachexia was defined as >5% weight loss (or >2% weight loss if body mass index <20 kg/m2), and precachexia was defined as 2% to 5% weight loss. We used multivariable logistic regression models to identify correlates of cachexia and multivariable Cox proportional hazard models to identify factors associated with overall survival.
Results: Of 604 patients with HCC, 201 (33.3%) had precachexia and 143 (23.7%) had cachexia at diagnosis, including 19.0%, 23.5%, 34.7%, and 34.0% of patients with Barcelona Clinic Liver Cancer stages 0/A, B, C, and D, respectively. Patients with cachexia were less likely to receive HCC treatment (odds ratio, 0.38; 95% confidence interval, 0.21-0.71) and had worse survival than those with precachexia or stable weight (11.3 vs 20.4 vs 23.5 months, respectively; P < .001). Cachexia remained independently associated with worse survival (hazard ratio, 1.43; 95% confidence interval, 1.11-1.84) after adjusting for age, sex, race, ethnicity, Child Pugh class, alpha-fetoprotein, Barcelona Clinic Liver Cancer stage, and HCC treatment.
Conclusions: Nearly 1 in 4 patients with HCC present with cachexia, including many with compensated cirrhosis or early stage tumors. The presence of cancer-associated weight loss appears to be an early and independent predictor of worse outcomes in patients with HCC.